Drugs / dTpa vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07596173 | Jun → Oct 2026 expected | — | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT05169905 | Feb → Aug 2022 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dTpa vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05169905 ↗ |
| Modality | Vaccine | “dTpa vaccine” NCT05169905 ↗ |